[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

Viazis et al., 2017 - Google Patents

Predictors of tissue healing in ulcerative colitis patients treated with anti-TNF

Viazis et al., 2017

View PDF
Document ID
18293754559230454662
Author
Viazis N
Giakoumis M
Bamias G
Goukos D
Koukouratos T
Katopodi K
Karatzas P
Triantos C
Tsolias C
Theocharis G
Daikos G
Ladas S
Karamanolis D
Mantzaris G
Publication year
Publication venue
Digestive and Liver Disease

External Links

Snippet

Aim To identify factors predicting mucosal healing in ulcerative colitis patients treated with anti-TNFα agents with or without azathioprine. Methods In a prospective, multicenter, one- year study biologic naïve patients aged 25–65 years, with corticosteroid-dependent or …
Continue reading at www.academia.edu (PDF) (other versions)

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay
    • G01N33/564—Immunoassay; Biospecific binding assay for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay
    • G01N33/574—Immunoassay; Biospecific binding assay for cancer
    • G01N33/57407—Specifically defined cancers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES OR MICRO-ORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Hybridisation probes
    • C12Q1/6883—Hybridisation probes for diseases caused by alterations of genetic material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/06—Gastro-intestinal diseases
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/56—Staging of a disease; Further complications associated with the disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/50—Determining the risk of developing a disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment; Prognosis

Similar Documents

Publication Publication Date Title
D’Haens et al. Development and validation of a test to monitor endoscopic activity in patients with Crohn’s disease based on serum levels of proteins
Assa et al. Proactive monitoring of adalimumab trough concentration associated with increased clinical remission in children with Crohn’s disease compared with reactive monitoring
Cleynen et al. Characteristics of Skin Lesions Associated With Anti–Tumor Necrosis Factor Therapy in Patients With Inflammatory Bowel Disease: A Cohort Study
Bertani et al. Serum oncostatin M at baseline predicts mucosal healing in Crohn's disease patients treated with infliximab
Jürgens et al. Levels of C-reactive protein are associated with response to infliximab therapy in patients with Crohn's disease
Casteele et al. Trough concentrations of infliximab guide dosing for patients with inflammatory bowel disease
Kohsaka et al. Treatment consensus for management of polymyositis and dermatomyositis among rheumatologists, neurologists and dermatologists
Panoulas et al. Association of interleukin-6 (IL-6)-174G/C gene polymorphism with cardiovascular disease in patients with rheumatoid arthritis: the role of obesity and smoking
Pauwels et al. Prediction of relapse after anti–tumor necrosis factor cessation in Crohn’s disease: individual participant data meta-analysis of 1317 patients from 14 studies
Dulai et al. Prognostic value of fecal calprotectin to inform treat-to-target monitoring in ulcerative colitis
Laharie et al. Steroid-free deep remission at one year does not prevent Crohn's disease progression: long-term data from the TAILORIX trial
JP2021177192A (en) Assessment of intestinal barrier function to improve treatment of inflammatory bowel disease
Bertani et al. Serum oncostatin M predicts mucosal healing in patients with inflammatory bowel diseases treated with anti-TNF, but not vedolizumab
Laharie et al. Evolution of endoscopic lesions in steroid-refractory acute severe ulcerative colitis responding to infliximab or cyclosporine
Yanai et al. Early indolent course of Crohn’s disease in newly diagnosed patients is not rare and possibly predictable
Cao et al. Association of neutrophil extracellular traps with fistula healing in patients with complex perianal fistulizing Crohn’s disease
Furfaro et al. Noninvasive assessment of postoperative disease recurrence in Crohn’s disease: a multicenter, prospective cohort study on behalf of the italian Group for Inflammatory Bowel Disease
Schneider et al. Expression and function of α4β7 integrin predict the success of vedolizumab treatment in inflammatory bowel disease
Choi et al. Combined medical and surgical approach improves healing of septic perianal Crohn's disease
Oliveira et al. Neutralizing Anti‒DNase 1 and‒DNase 1L3 antibodies impair neutrophil extracellular traps degradation in hidradenitis suppurativa
Viazis et al. Predictors of tissue healing in ulcerative colitis patients treated with anti-TNF
Venkateswaran et al. Longitudinal DNA methylation profiling of the rectal mucosa identifies cell-specific signatures of disease status, severity and clinical outcomes in ulcerative colitis cell-specific DNA methylation signatures of UC
Magro et al. How many biomarker measurements are needed to predict prognosis in Crohn's disease patients under infliximab?—A prospective study
Cassinotti et al. Noninvasive monitoring after azathioprine withdrawal in patients with inflammatory bowel disease in deep remission
Kurti et al. ‘Treat to Target'-Lessons Learnt